Trevi Therapeutics, Inc. (TRVI)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Trevi Therapeutics, Inc. (TRVI) is up 41.5% since the beginning of the year. At $18 per share, TRVI is trading just below its 52-week high of $18. Investors who bought $1,000 worth of TRVI shares 5 years ago would now be looking at an investment worth $8,124.

Trevi Therapeutics, Inc. (TRVI) has returned 41.45% so far this year and 197.15% over the past 12 months.

Based on dividend-adjusted daily data since May 7, 2019, TRVI's average daily return is +0.21%, while the average monthly return is +5.22%. At this rate, an investment would double in approximately 1.1 years.

Historically, 48% of months were positive and 52% were negative. The best month was Mar 2022 with a return of +243.8%, while the worst month was Sep 2022 at -51.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, TRVI closed higher 47% of trading days. The best single day was Mar 31, 2020 with a return of +92.4%, while the worst single day was Mar 30, 2020 at -25.7%.

Trevi Therapeutics, Inc. has an annualized alpha of 62.64%, beta of 0.36, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since May 07, 2019.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (43.52%) than losses (42.55%) - typical of diversified or defensive assets.
• Beta of 0.36 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TRVI ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Trevi Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Trevi Therapeutics, Inc. was 95.45%, occurring on Feb 23, 2022. Recovery took 913 trading sessions.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Trevi Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Trevi Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.